{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:03:10Z","timestamp":1760731390077},"reference-count":12,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T00:00:00Z","timestamp":1606089600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,2,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To evaluate the in vivo efficacy of a dual carbapenem combination containing imipenem plus meropenem against carbapenem-resistant Acinetobacter baumannii producing carbapenemases OXA-23 or OXA-58.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>An experimental model of peritonitis using C57BL\/6J female mice was developed and the minimum lethal doses were calculated for infections due to OXA-23 or OXA-58 producers of A. baumannii clinical isolates. The efficacies of the carbapenems in monotherapy and in combination were tested.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Meropenem was better than imipenem in mice infected with either of the carbapenem-resistant A. baumannii (CRAb) strains. The combination of meropenem plus imipenem significantly improved the clearance of CRAbs from spleen compared with non-treated groups. The carbapenem-containing combination was better than imipenem for treating mice infected with both carbapenemase producers. In blood, the carbapenem combination significantly decreased the bacterial load of the OXA-23 producers compared with imipenem or meropenem used in monotherapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>These results suggest that dual carbapenem combination could be an option for the treatment of infections due to carbapenemase-producing A. baumannii such as OXA-23 and OXA-58 producers.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkaa487","type":"journal-article","created":{"date-parts":[[2020,11,5]],"date-time":"2020-11-05T20:11:44Z","timestamp":1604607104000},"page":"680-683","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy of dual carbapenem treatment in a murine sepsis model of infection due to carbapenemase-producing <i>Acinetobacter baumannii<\/i>"],"prefix":"10.1093","volume":"76","author":[{"given":"T","family":"Cebrero-Cangueiro","sequence":"first","affiliation":[{"name":"Institute of Biomedicine of Seville (IBiS), Virgen del Rocio University Hospital\/CSIC\/University of Seville, Seville, Spain"},{"name":"Department of Medicine, University of Seville, Seville, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Nordmann","sequence":"additional","affiliation":[{"name":"Emerging Antibiotic Resistance Unit, Medical and Molecular Microbiology, Department of Medicine, University of Fribourg, Fribourg, Switzerland"},{"name":"INSERM European Unit (LEA-IAME, France), University of Fribourg, Fribourg, Switzerland"},{"name":"National Reference Center for Emerging Antibiotic Resistance, University of Fribourg, Fribourg, Switzerland"},{"name":"University of Lausanne and University Hospital Center, Lausanne, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Carretero-Ledesma","sequence":"additional","affiliation":[{"name":"Institute of Biomedicine of Seville (IBiS), Virgen del Rocio University Hospital\/CSIC\/University of Seville, Seville, Spain"},{"name":"Clinical Unit of Infectious Diseases, Microbiology, and Preventive Medicine, Virgen del Rocio University Hospital, Seville, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Pach\u00f3n","sequence":"additional","affiliation":[{"name":"Institute of Biomedicine of Seville (IBiS), Virgen del Rocio University Hospital\/CSIC\/University of Seville, Seville, Spain"},{"name":"Department of Medicine, University of Seville, Seville, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M E","family":"Pach\u00f3n-Ib\u00e1\u00f1ez","sequence":"additional","affiliation":[{"name":"Institute of Biomedicine of Seville (IBiS), Virgen del Rocio University Hospital\/CSIC\/University of Seville, Seville, Spain"},{"name":"Clinical Unit of Infectious Diseases, Microbiology, and Preventive Medicine, Virgen del Rocio University Hospital, Seville, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,11,23]]},"reference":[{"key":"2021021208583853800_dkaa487-B1","first-page":"15","article-title":"Carbapenem resistance: overview of the problem and future perspectives","volume":"3","author":"Meletis","year":"2016","journal-title":"Ther Adv Infect Dis"},{"key":"2021021208583853800_dkaa487-B2","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S1473-3099(17)30753-3","article-title":"Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis","volume":"18","author":"Tacconelli","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2021021208583853800_dkaa487-B3","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.ijantimicag.2015.03.001","article-title":"Emerging broad-spectrum resistance in Pseudomonas aeruginosa and Acinetobacter baumannii: mechanisms and epidemiology","volume":"45","author":"Potron","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"2021021208583853800_dkaa487-B4","doi-asserted-by":"crossref","first-page":"151.","DOI":"10.3389\/fpubh.2019.00151","article-title":"The \u201cOld\u201d and the \u201cNew\u201d antibiotics for MDR gram-negative pathogens: for whom, when, and how","volume":"7","author":"Karaiskos","year":"2019","journal-title":"Front Public Health"},{"key":"2021021208583853800_dkaa487-B5","doi-asserted-by":"crossref","first-page":"S521","DOI":"10.1093\/cid\/ciz824","article-title":"Epidemiology and diagnostics of carbapenem resistance in gram-negative bacteria","volume":"69","author":"Nordmann","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2021021208583853800_dkaa487-B6","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jinf.2019.10.003","article-title":"In-vitro evaluation of a dual carbapenem combination against carbapenemase-producing Acinetobacter baumannii","volume":"80","author":"Nordmann","year":"2020","journal-title":"J Infect"},{"key":"2021021208583853800_dkaa487-B7"},{"key":"2021021208583853800_dkaa487-B8","doi-asserted-by":"crossref","first-page":"4464","DOI":"10.1128\/AAC.02708-15","article-title":"Efficacy of lysophosphatidylcholine in combination with antimicrobial agents against Acinetobacter baumannii in experimental murine peritoneal sepsis and pneumonia models","volume":"60","author":"Parra Millan","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2021021208583853800_dkaa487-B9","doi-asserted-by":"crossref","first-page":"e01446-17.","DOI":"10.1128\/AAC.01446-17","article-title":"Activity of Meropenem-Vaborbactam in mouse models of infection due to KPC-producing carbapenem-resistant enterobacteriaceae","volume":"62","author":"Sabet","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2021021208583853800_dkaa487-B10","doi-asserted-by":"crossref","first-page":"912","DOI":"10.3389\/fmicb.2018.00912","article-title":"Efficacy of colistin and its combination with rifampin in vitro and in experimental models of infection caused by carbapenemase-producing clinical isolates of Klebsiella pneumoniae","volume":"9","author":"Pachon-Ibanez","year":"2018","journal-title":"Front Microbiol"},{"key":"2021021208583853800_dkaa487-B11","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1517\/14656566.2012.729820","article-title":"Therapeutic options for Acinetobacter baumannii infections: an update","volume":"13","author":"Vila","year":"2012","journal-title":"Expert Opin Pharmacother"},{"key":"2021021208583853800_dkaa487-B12","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s13054-017-1769-z","article-title":"Double carbapenem as a rescue strategy for the treatment of severe carbapenemase-producing Klebsiella pneumoniae infections: a two-center, matched case-control study","volume":"21","author":"De Pascale","year":"2017","journal-title":"Crit Care"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/76\/3\/680\/36241186\/dkaa487.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/76\/3\/680\/36241186\/dkaa487.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,13]],"date-time":"2021-02-13T00:26:22Z","timestamp":1613175982000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/76\/3\/680\/5998969"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,23]]},"references-count":12,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,11,23]]},"published-print":{"date-parts":[[2021,2,11]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaa487","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,3,1]]},"published":{"date-parts":[[2020,11,23]]}}}